BioSpace News Archive

2019 National Nurse Practitioner Sample Survey Compensation Results Released

Attendees at HIMSS20 who want to learn how analytics, artificial intelligence (AI) and machine learning (ML) can be used more easily and effectively to achieve peak business health will want to stop by the VisiQuate Innovation Live booth, #8200-38 (Hall E).

Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today reported its financial and operational results for the year ended December 31, 2019.

Neuraly, a clinical stage biotechnology company pioneering disease-modifying agents for neurodegenerative disorders, today announced the dosing of the first patient in its Phase 2 clinical trial of NLY01 for Parkinson’s disease.

Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today reported full year financial results for year ended December 31, 2019 and provided an update on corporate progress.

Kura Oncology, Inc. (Nasdaq: KURA),today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company’s lead drug candidate, tipifarnib, for the treatment of adult patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL), follicular T-cell lymphoma (FTCL) and nodal peripheral T-cell lymphoma with T follicular helper (TFH) phenotype.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patients in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis (NASH).

Fast-growing, HIMSS Davies Award of Excellence-winning tertiary health system to collaborate on developing new Cores apps and offer the solutions to other health systems

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that the company will present an abstract in a poster session at the upcoming AACR Annual Meeting, which is being held April 24 – 29, 2020 at the San Diego Convention Center.

Enabling Low-Cost, High-Volume Sequencing of Drug-Resistant Pathogens for Hospital Infection Control and Surveillance